Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L; ECHELON-2 Study Group. Horwitz S, et al. Among authors: fanale m. Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4. Lancet. 2019. PMID: 30522922 Free PMC article. Clinical Trial.
Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1.
Crosswell HE, LaCasce AS, Bartlett NL, Straus DJ, Savage KJ, Zinzani PL, Collins GP, Fanale M, Fenton K, Dong C, Miao H, Grigg AP. Crosswell HE, et al. Among authors: fanale m. Haematologica. 2024 Mar 1;109(3):982-987. doi: 10.3324/haematol.2023.283303. Haematologica. 2024. PMID: 37794803 Free PMC article. No abstract available.
Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United States.
Barta SK, Liu N, DerSarkissian M, Chang R, Ye M, Duh MS, Surinach A, Fanale M, Yu KS. Barta SK, et al. Among authors: fanale m. Clin Lymphoma Myeloma Leuk. 2024 Feb;24(2):e21-e32.e4. doi: 10.1016/j.clml.2023.10.001. Epub 2023 Oct 11. Clin Lymphoma Myeloma Leuk. 2024. PMID: 37919137 Free article. Clinical Trial.
Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Stage III or IV Classic Hodgkin Lymphoma Treated With Frontline ABVD: A Retrospective Database Review in the United States.
Winter A, Liu N, Surinach A, Fanale M, Yu KS, Narkhede M. Winter A, et al. Among authors: fanale m. Clin Lymphoma Myeloma Leuk. 2023 Jul;23(7):527-534. doi: 10.1016/j.clml.2023.03.015. Epub 2023 Mar 30. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37121857 Free article.
Observations of Oncologists on Treatment Selection With Interim Positron Emission Tomography-Adapted Approaches in Classic Hodgkin Lymphoma: The Real-World CONNECT Study.
Parsons SK, Yu KS, Liu N, Kumar S, Fanale MA, Holmes K, Flores C, Surinach A, Flora DR, Evens AM. Parsons SK, et al. Among authors: fanale ma. JCO Oncol Pract. 2023 Jun;19(6):e867-e876. doi: 10.1200/OP.22.00811. Epub 2023 Mar 22. JCO Oncol Pract. 2023. PMID: 36947720 Free PMC article. Clinical Trial.
Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced-Stage Classical Hodgkin Lymphoma.
Lee HJ, Ramchandren R, Friedman J, Melear JM, Flinn IW, Burke JM, Linhares Y, Gonzales PA, Peterson M, Raval M, Chintapatla R, Feldman TA, Yimer HA, Islas-Ohlmayer M, Patel A, Metheny L, Dean A, Rana V, Gandhi MD, Renshaw JS, Ho L, Fanale MA, Guo W, Yasenchak CA. Lee HJ, et al. Among authors: fanale ma. Blood. 2024 Dec 2:blood.2024024681. doi: 10.1182/blood.2024024681. Online ahead of print. Blood. 2024. PMID: 39622165
164 results